Your browser doesn't support javascript.
loading
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts.
Dougherty, Dane H; Kwakkenbos, Linda; Carrier, Marie-Eve; Salazar, Gloria; Assassi, Shervin; Baron, Murray; Bartlett, Susan J; Furst, Daniel E; Gottesman, Karen; van den Hoogen, Frank; Malcarne, Vanessa L; Mouthon, Luc; Nielson, Warren R; Poiraudeau, Serge; Sauvé, Maureen; Boire, Gilles; Bruns, Alessandra; Chung, Lorinda; Denton, Christopher; Dunne, James V; Fortin, Paul; Frech, Tracy; Gill, Anna; Gordon, Jessica; Herrick, Ariane L; Hinchcliff, Monique; Hudson, Marie; Johnson, Sindhu R; Jones, Niall; Kafaja, Suzanne; Larché, Maggie; Manning, Joanne; Pope, Janet; Spiera, Robert; Steen, Virginia; Sutton, Evelyn; Thorne, Carter; Wilcox, Pearce; Thombs, Brett D; Mayes, Maureen D.
Afiliação
  • Dougherty DH; Department of Internal Medicine, Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, USA.
  • Kwakkenbos L; Department of Psychiatry, McGill University, Montreal, QC, Canada.
  • Carrier ME; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
  • Salazar G; Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, the Netherlands.
  • Assassi S; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
  • Baron M; Department of Internal Medicine, Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, USA.
  • Bartlett SJ; Department of Internal Medicine, Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, USA.
  • Furst DE; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
  • Gottesman K; Department of Medicine, McGill University, Montreal, QC, Canada.
  • van den Hoogen F; Department of Medicine, McGill University, Montreal, QC, Canada.
  • Malcarne VL; Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Mouthon L; McGill University Health Center, Montréal, QC, Canada.
  • Nielson WR; Division of Rheumatology, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Poiraudeau S; Medicine, University of Washington, Seattle, WA, USA.
  • Sauvé M; Medicine, University of Florence, Florence, Italy.
  • Boire G; Scleroderma Foundation, Danvers, MA, USA.
  • Bruns A; Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Chung L; Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
  • Denton C; Department of Psychology, San Diego State University, San Diego, CA, USA.
  • Dunne JV; San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego, CA, USA.
  • Fortin P; Médecine interne, Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, France.
  • Frech T; Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares, vascularites nécrosantes et sclérodermie systémique, Hôpital Cochin, Paris, France.
  • Gill A; Beryl & Richard Ivey Rheumatology Day Programs, St Joseph's Health Care, London, ON, Canada.
  • Gordon J; Lawson Health Research Institute, London, ON, Canada.
  • Herrick AL; Médecine interne, Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, France.
  • Hinchcliff M; Service de Médecine Physique et Réadaptation, Hôpital Cochin, France.
  • Hudson M; IFR Handicap INSERM, Paris, France.
  • Johnson SR; Scleroderma Society of Ontario, Hamilton.
  • Jones N; Scleroderma Society of Canada, Ottawa, ON, Canada.
  • Kafaja S; Département de médecine, Sherbrooke University, Sherbrooke, QC, Canada.
  • Larché M; Département de médecine, Sherbrooke University, Sherbrooke, QC, Canada.
  • Manning J; Medicine - Med/Immunology & Rheumatology, Stanford University, Stanford, CA, USA.
  • Pope J; Department of Rheumatology, Royal Free London Hospital, London, UK.
  • Spiera R; Rheumatology, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
  • Steen V; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Sutton E; Département de médecine, Université Laval, Québec, QC, Canada.
  • Thorne C; Internal Medicine, University of Utah, Salt Lake City, UT, USA.
  • Wilcox P; Rheumatology, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
  • Thombs BD; Department of Rheumatology, Hospital for Special Surgery, New York City, NY, USA.
  • Mayes MD; Division of Musculoskeletal & Dermatological Sciences, University of Manchester, Salford Royal NHS Foundation Trust, Manchester, UK.
Rheumatology (Oxford) ; 57(9): 1623-1631, 2018 09 01.
Article em En | MEDLINE | ID: mdl-29868924
ABSTRACT

Objectives:

The Scleroderma Patient-centered Intervention Network (SPIN) Cohort is a web-based cohort designed to collect patient-reported outcomes at regular intervals as a framework for conducting trials of psychosocial, educational, self-management and rehabilitation interventions for patients with SSc. The aim of this study was to present baseline demographic, medical and patient-reported outcome data of the SPIN Cohort and to compare it with other large SSc cohorts.

Methods:

Descriptive statistics were used to summarize SPIN Cohort characteristics; these were compared with published data of the European Scleroderma Trials and Research (EUSTAR) and Canadian Scleroderma Research Group (CSRG) cohorts.

Results:

Demographic, organ involvement and antibody profile data for SPIN (N = 1125) were generally comparable with that of the EUSTAR (N = 7319) and CSRG (N = 1390) cohorts. There was a high proportion of women and White patients in all cohorts, though relative proportions differed. Scl70 antibody frequency was highest in EUSTAR, somewhat lower in SPIN, and lowest in CSRG, consistent with the higher proportion of interstitial lung disease among dcSSc patients in SPIN compared with in CSRG (48.5 vs 40.3%). RNA polymerase III antibody frequency was highest in SPIN and remarkably lower in EUSTAR (21.1 vs 2.4%), in line with the higher prevalence of SSc renal crisis (4.5 vs 2.1%) in SPIN.

Conclusion:

Although there are some differences, the SPIN Cohort is broadly comparable with other large prevalent SSc cohorts, increasing confidence that insights gained from the SPIN Cohort should be generalizable, although it should be noted that all three cohorts include primarily White participants.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Satisfação do Paciente / Assistência Centrada no Paciente / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Satisfação do Paciente / Assistência Centrada no Paciente / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos